Largecap equities will outpace midcaps over the next one to two quarters as institutional capital seeks shelter from stretched valuations. Foreign institutional desks are hunting for liquid entry points. Blue chips offer the capacity to absorb those multi-billion-dollar inflows when risk appetite turns. Midcaps, meanwhile, look expensive.
Broader market multiples face a de-rating over the next 12 months, warned Nitin Bhasin, Head of Institutional Equities at Ambit. Corporate earnings across India's largest listed companies are picking up speed, creating a valuation cushion that mid-tier shares currently lack.
The valuation spread between largecaps and midcaps has stretched beyond historical comfort levels. When foreign portfolio investors rotate back into Indian equities, liquidity constraints dictate where that money lands. Midcaps cannot swallow deep global allocations without distorting market pricing. Largecaps can.
Given the valuation differential between largecaps and midcaps, given the ability to deploy much larger capital of the global capital when it wants to move into India, we still continue to prefer largecaps at least for the next quarter or two," said Bhasin.
The math is straightforward. Institutional funds seeking hundred-million-dollar deployment tickets require deep order books. Largecaps offer that liquidity without generating slippage. Recent quarterly scorecards have validated that stance, with largecap balance sheets showing sustained operational recovery.
A ground-level review of retail activity across India reveals resilient discretionary spending. Ground checks tracking trade activity over the past five to six weeks confirm healthy demand across passenger vehicles, apparel, footwear, jewelry, and consumer durables. Selected retail categories recorded sharp demand acceleration heading into the festival peak.
Yet the play is not limited to retail shelf space. Ambit is channeling client exposure through third-party delivery networks and freight handlers that bridge modern retail with end consumers.
"Logistics and delivery companies can benefit from this broader consumption trend as they work with multiple e-commerce and consumer platforms," Bhasin stated, observing that multi-platform handlers remove single-brand operational risks.
| Sectoral Allocation Stance | Primary Asset Classes | Core Thesis & Valuation Driver | Expected Horizon |
|---|---|---|---|
| Overweight | Largecap Banks & Financials | High predictability, clean balance sheets | 1 to 2 Quarters |
| Overweight | Direct & Indirect Consumption | Resilient festive volume, multi-platform retail | 2 to 4 Quarters |
| Neutral to Selective | Logistics & Delivery Networks | Diversified revenue stream across e-commerce | 6 Months |
Capital is moving out of overheated capital-expenditure plays. Industrial order books drove dramatic share rallies across infrastructure and capital goods over the past year, but prices now run well ahead of earnings fundamentals. Ambit is pulling back from those crowded trades.
"I would bet my money slightly more on consumption and banks in the next couple of quarters versus capex-intensive themes," Bhasin noted. Private and state lenders offer cleaner earnings predictability at defensible forward price-to-earnings ratios.
Healthcare portfolios are also seeing reductions. While Contract Development and Manufacturing Organisation (CDMO) operators remain structurally more scalable and less vulnerable to operational risks than hospital chains, pricing across both pockets has uncoupled from balance sheets. Trading momentum in healthcare has shifted toward narrative chasing rather than underlying cash generation.
A market-wide re-rating cycle appears increasingly unlikely as global rates and domestic earnings adjust. Institutional desks are instead positioning for a stock-picker's phase over the next six months—one centered on banking balance sheets, festive retail tailwinds, and largecap liquidity.
| Underweight |
| Capex-Intensive Industrials |
| Stretched multiples following aggressive run-ups |
| 12 Months |
| Underweight | Healthcare & Hospitals / CDMO | Narrative-driven pricing overshooting metrics | Next 2 Quarters |